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Abstract
Background: Chlamydia trachomatis may cause multiple different urogenital tract disorders, but current
non-culture assays for rapid screening of C. trachomatis typically use immunochromatography-based methods. We
established another new rapid non-culture method for detection of C. trachomatis based on the measurement of
α-mannosidase enzymatic activity in urogenital tract specimens.
Method: To evaluate the performance of this method, α-mannosidase activities of C. trachomatis serotype D strain、
and 29 standard strains related to clinical urogenital pathogens were investigated. Furthermore, 553 urogenital tract
specimens were used for clinical assays via cell culture method and ligase chain reaction method (LCR), adopting an
expanded gold standard.
Results: Only C. trachomatis was positive for α-mannosidase activity among different types of microbes tested in the
research. When prostate fluid specimens, which have some interfering activity, were excluded, the sensitivity and
specificity of the enzymatic method were 91.8% (78/85) and 98.3% (409/416), respectively. There were no significant
differences (P > 0.05).
Conclusions: These results showed that α-mannosidase activity could be utilised as a screening marker of C.
trachomatis infection.
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Background
C. trachomatis infection is the most common sexually
transmitted disease (STD) in the United States [1].
Mounting evidence has indicated that it not only evokes
nongonococcal urethritis (NGU), cervicitis, pelvic
inflammatory disease (PID), salpingitis, orchitis, and
epididymitis, but also increases risk of invasive cervical
cancer [2,3] and gives rise to serious reproductive
disorders such as infertility [4,5], miscarriage/premature
birth/missed miscarriage [6-9], and neonatal conjunctiv-
itis [10].
A large number of methods have been established for
screening and diagnosis of C. trachomatis infection [11].
Nevertheless, few of these assays meet the requirements
of outpatient diagnosis, especially in terms of sensitivity,
specificity, time, and simplicity of operation. Currently,
non-culture assays for C. trachomatis screening typically
adopt immunochromatography-based methods. Tech-
nologies based on chromogenic reactions of specific
microbial enzymes have been widely applied in bacterial
identification systems and chromogenic media [12-15].
However, no chromogenic assay for detecting C. tracho-
matis has been made available to date.
Our previous findings [16] suggested that C. trachomatis
might have very high α-mannosidase activity. The purpose
of the study was to establish a novel screening method for
C. trachomatis infection without culture that would be
rapid and convenient for use in outpatient clinics.
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All patients were treated in accordance with the Helsinki
Declaration on the participation of human subjects in med-
ical research. Ethics approval for the study was obtained
from the First Affiliated Hospital Ethics Committee of
Zhengzhou University (Approved No. 20100802) and
Henan Provincial People’s Hospital Ethics Committee
(Approved No. 20100901).
Organisms
Reference strains and cell lines were obtained from the
organisations shown in Table 1.
Specimens
This study evaluated 553 specimens from clinical patients
attending the STD (257, 46.47%) and Gynaecology
(296, 53.53%) clinics at the First Affiliated Hospital of
Zhengzhou University (Zhengzhou, China) and the Henan
Provincial People’s Hospital (Zhengzhou, China), respect-
ively. For the 203 male cases, three urethral discharge spe-
cimens (151 outpatients, 74.38%) or three prostate
massage liquid specimens (52 outpatients, 25.62%) were
collected with sterile rayon swabs (Copan, Brescia, Italy).
Meanwhile, for the 350 female cases, three cervical secre-
tion specimens (232 outpatients, 66.29%) or three vaginal
secretion specimens (118 outpatients, 33.71%) were col-
lected with sterile rayon swabs using vaginal forceps.
Table 1 Reference strains and cell line
Strains or cell line Accession numbers Organizations
Acinetobacter baumannii ATCC19606 Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida albicans ATCC10231 Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida glabrata ATCC15126 Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida guilliermondii ATCC6260 Harmony Biotechnology Co., Ltd (Shanghai, China)
Candida krusei ATCC14243 Harmony Biotechnology Co., Ltd (Shanghai, China)
Cryptococcus neoformans CMCC(F)D2q China Medical Microbiological Culture Collection Center (fungi)(Nanjing, China)
Candida parapsilosis CGMCC2.1846 China General Microbiological Culture Collection Center (Beijing, China)
Candida tropicalis ATCC750 Harmony Biotechnology Co., Ltd (Shanghai, China)
Chlamydia trachomatis Serovar D VR-885 American Type Culture Collection(Manassas, USA)
Enterococcus faecalis ATCC29212 Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Enterococcus faecium ATCC700221 Harmony Biotechnology Co., Ltd (Shanghai, China)
Escherichia coli ATCC25922 Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
Gardnerella vaginalis ATCC14018 Harmony Biotechnology Co., Ltd (Shanghai, China)
Haemophilus influenzae ATCC10211 Harmony Biotechnology Co., Ltd (Shanghai, China)
Klebsiella pneumoniae CMCC46117 Tianhe Microorganism Reagent Co., Ltd (Hangzhou, China)
McCony CRL-1696 American Type Culture Collection(Manassas, USA)
Mycoplasma hominis ATCC15488 Harmony Biotechnology Co., Ltd (Shanghai, China)
Neisseria gonorrhoeae ATCC19424 Henan Provincial Center for Disease Control and Prevention (Zhengzhou, China)
Pseudomonas aeruginosa ATCC25619 Land Bridge Biotechnology Co., Ltd (Beijing, China)
Proteus mirabilis CMCC(B)49005 Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Salmonella enteritidis ATCC13076 Land Bridge Biotechnology Co., Ltd (Beijing, China)
Staphylococus aureus ATCC25923 Henan Provincial Institute of Food and Drug Control (Zhengzhou, China)
Staphylococcus aureus ATCC29213 Capital Institute of Pediatrics (Beijing, China)
Staphylococcus epidermidis ATCC12228 Huankai Microbial Sci & Tech. Co., Ltd (Guangzhou, China)
Staphylococus saprophyticus ATCC49453 Land Bridge Biotechnology Co., Ltd (Beijing, China)
Stenotrophomonas maltophilia ATCC17666 Land Bridge Biotechnology Co., Ltd (Beijing, China)
Streptococus agalactiae ATCC13813 Harmony Biotechnology Co., Ltd (Shanghai, China)
Streptococus pneumoniae ATCC49619 National Center for Clinical Laboratory (Beijing, China)
Streptococus pyogenes ATCC19615 Harmony Biotechnology Co., Ltd (Shanghai, China)
Trichomonas vaginalis ATCC30001 Harmony Biotechnology Co., Ltd (Shanghai, China)
Ureaplasma urealyticum ATCC15531 Harmony Biotechnology Co., Ltd (Shanghai, China)
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Three swabs collected for each specimen, were no signifi-
cant differences in sampling link and randomly used with
three methods. None of the patients received any antibio-
tics one week before sample collection, when samples
were taken before diagnosis.
Media, culture and inoculation
Liquid media A (LMA) and liquid media B (LMB) were
prepared for mycoplasma culture. The components of
LMA were shown in Table 2, but LMB consisted of
50 mg/l phenol red besides LMA components. The media
were inoculated with both Ureaplasma urealyticum and
Mycoplasma hominis and analyzed by using the colour-
changing unit (CCU) method, as previously reported [17].
Once the concentrations of mycoplasma reached 106
CCU/ml in LMB, the cultures of LMA should be immedi-
ately stored at 4°C.
Trichomonas vaginalis was obtained after 24 h
incubation at 37°C in Trichomonas medium (Oxoid,
Basingstoke, UK) supplemented with 8% horse blood
and 1,000 units/ml penicillin sodium and 500 mg/ml
streptomycin. The collection was stored at 4°C.
All other micro-organisms except C. trachomatis used in
the study were inoculated and cultured as described in
Table 3. The collections described in Table 3 were resus-
pended to 0.5 McFarland standards in a sterile solution
of 0.9% NaCl and then stored at 4°C.
Enzymatic method
The enzymatic method was based on the substrate of
α-D-mannosidase. The substrate solution contained
1.5 mg/ml 6-chloro-3-indolyl-α-D-mannoside (J&K,
Shanghai, China), 100 mM citrate buffer (pH 4.0), and
1% Triton X-100. The sample diluent was 0.9% NaCl.
The chromogenic reagent contained 0.08% fast violet B
salt (J&K, Shanghai, China). Aliquots (50 μl) of substrate
solution and chromogenic reagent were added sequentially
into sample solutions (extracted from every swab sample
with 500 μl sample diluent) or the aforementioned micro-
bial suspensions as well as the chlamydial suspension
mentioned in the section called limit of detection (LOD)
of the enzymatic method. The result was considered to be
positive (OD512 ≧ 0.150) if the colour changed from
colourless to red or brown after 15 min of incubation at
37°C; otherwise, the result was considered to be negative
(OD512 < 0.150). The suspensions containing bacteria or
cells was centrifuged at 5,000 rpm for 5 min, and then
OD512 value of the supernatants were measured.
LOD of the enzymatic method
McCoy cells infected with C. trachomatis serovar D were
stored at −80°C, and frozen-thawed twice to obtain chla-
mydial suspension before use. Serial 10-fold dilutions of the
chlamydial suspension were inoculated in six duplicate into
wells (100 μl/well) of cycloheximide-treated McCoy cell
monolayers that had been incubated with MEM medium
(Gibco, Grand Island, NY, USA) in a 96-well flat-bottom
microtiter plate (Nunc Inc., Roskilde, Denmark) at 37°C
under 5% CO2 for 48 h. Inclusion body titers of the chla-
mydial supernatant were quantified by titrating the number
of inclusion-forming units (IFU). The contents of each well
were stained with a C. trachomatis direct fluorescent anti-
body kit (Academy of Military Medical Science, Beijing,
China) and examined by microscopy for IFU counts. The
average IFU of each dilution culture of three replicate wells
was taken as the concentration of C. trachomatis in the
corresponding dilution of the chlamydia suspension. Each
dilution culture of the other three replicate wells was
examined via the enzymatic method after collection to de-
termine the LOD for C. trachomatis of the enzymatic
method. 10-1 u/ml α-D-mannosidase (EC3.2.1.24; Sigma,
USA) solution was 5-fold serially diluted to 10-4 u/ml.
These enzyme solutions fold-diluted were detected via the
enzymatic method to determine the LOD for α-D-
mannosidase.
Reference method
Cell culture and LCR method were used to evaluate the
clinical performance of the enzymatic method. The
swabs used for culture were dipped directly into inciden-
tal transport medium (Copan, Brescia, Italy) and cul-
tured according to the aforementioned method. The
cultures were tested using a C. trachomatis direct
fluorescent antibody kit. LCR was carried out using the
LCx C. trachomatis assay (Abbott Laboratories, Abbott
Park, Israel) according to the manufacturer’s instruc-
tions. Although culture method has a good specificity,
its sensitivity may be influenced by various factors.
Table 2 Composition of LMA for Mycoplasma (per liter) *
Ingredient Concentration Ingredient Concentration
NaCl 6.4 g Beef heart extract
power
7.2 g
CaCl2 112 mg Yeast extract
power
2.72 g
MgCl2·6H2O 80 mg Peptone 8.0 g
MgSO4·7H2O 80 mg Horse serum 200 ml
KCl 320 mg Penicillin sodium 1,000,000 units
Na2HPO4·12H2O 122 mg Ampicillin sodium 375 mg
KH2PO4 48 mg Vancomycin 40 mg
Cysteine
hydrochloride
0.8 g Polymyxin B 40,000 units
Arginine
hydrochloride
4.0 g Nystatin 15,000 USP
units
Urea 4.0 g
*Adjusted to pH 6.25.
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Therefore, the research adopted an “expanded gold
standard” [18-20] described as follows: any positive by
either culture or LCR was classified as a true positive,
whatever the result of the enzymatic method.
Results
In our developed assay, only C. trachomatis samples
tested was positive for α-D-mannosidase activity; but
OD512 of both other organisms and cell cultures which
were not inoculated with C. trachomatis used in the
study was all below 0.100, which fell into the range of
negative results negative with 0.150 (OD512) as the cut-
off value, even if the reactions were allowed to proceed
for 1 h at 37°C. Of the 553 clinical samples, 132 samples
were positive with OD512 ranging from 0.161 to 1.955,
and 421 samples were negative with OD512 ranging from
0.013 to 0.142. C. trachomatis detection results of 553
cases with culture, LCR and enzymatic method used an
expanded gold standard as the reference standard were
showed in Table 4. The enzymatic method was least reli-
able when prostate specimens were used. The sensitivity
of the enzymatic method was 91.5% (95% confidence
interval [CI], 85.9% to 97.1%), and the specificity of this
method was 90.0% (95% CI, 87.3% to 92.7%) (Table 5).
The sensitivity and specificity of the LCR were 94.7%
(95% CI, 90.2% to 99.2%) and 100% (95% CI, 100.0% to
100.0%), respectively. However, in those specimens other
than prostate fluid samples, the sensitivity and specificity
of the enzymatic method were 91.8% (95% CI, 86.0% to
97.6%) and 98.3% (95% CI, 97.1% to 99.5%), in the
meantime the sensitivity and specificity of the LCR were
95.3% (95% CI, 90.8% to 99.8%) and 100% (95% CI,
100% to 100%) (Table 6), respectively. There were no sig-
nificant differences in performance between the enzymatic
method and the expanded gold standard (P > 0.05).
The result of the chlamydial suspension quantified
with 617 IFU/ml was light pink, and might be consid-
ered positive (OD512 = 0.162). Meanwhile, the result of
the chlamydial suspension was colourless if quantified
with 126 IFU/ml, and might be considered negative
(OD512 = 0.098). Therefore, the LOD was 617 IFU/ml
for C. trachomatis. In addition, the LOD was 10-3 u/ml
(OD512 = 0.155) for α-D-mannosidase.
Discussion
There are various well-known methods for detecting
C. trachomatis, including cell culture-, immunology-,
molecular biology-, and biochemistry-based methods.
Cell culture is complicated to perform and requires ex-
perience to produce accurate results, and it also has
more stringent requirements for the sampling swabs and
transporting before inoculation [21,22]. Therefore, cell
culture is rarely used in clinics. Among the available
immunological methods, serological tests for the
C. trachomatis antibody have significant limitations [23],
but methods for C. trachomatis antigen detection
(mainly referring to the lipopolysaccharide, LPS), espe-
cially immunochromatography-based methods, have
been widely used due to their simplicity of operation.
There are two ways to extract the LPS antigen for
C. trachomatis immunochromatographic assays: heat ex-
traction and acid extraction. Neither of these methods
guarantees the full extraction of LPS as an intact anti-
gen, which influences the sensitivity of this method. The
biochemical detection of glycogen in C. trachomatis
inclusions [24] is greatly affected by Candida spp. that
often exist in these specimens and are especially com-
mon during the female menstrual cycle and pregnancy.
With the increasing glycogen in vaginal epithelial cells,
this method may also cause false positives. The detection
of C. trachomatis in the United States and Europe has
mainly focused on molecular biology methods [25-30].
Although these methods are both high sensitivity and
high specificity, it can be challenging for molecular biol-
ogy methods to meet the requirements of the actual ap-
plication in clinical screening.
Enzymatic studies of C. trachomatis, especially for
enzymes with diagnostic significance, have not been
reported in the literature. Previous studies [31] and our
research have shown that C. trachomatis secretes extra-
cellular enzymes with high α-D-mannosidase activity.
Although some organisms used in the study such as
C. albicans have genes encoding α-1,2-mannosidase
Table 3 The media and culture methods for bacteria and
candida
Strains Media Temp. Time
Bacteria
A. baumannii, E. faecalis, Blood agar base a 37°C 24 h
E. faecium, E. coli, K.
pneumoniae,
P. mirabilis, P. aeruginosa,
S. enteritidis, S. aureus,
S. epidermidis, S. saprophyticus,
S. maltophilia, S. agalactiae,
S. pyogenes, S. pneumoniae
G. vaginalis * Blood agar base 37°C 48 h
H. influenzae * Thayer Martin media b 24 h
N. gonorrhoeae * 48 h
Candida
C. albicans, C. tropicalis, Sabouraud dextrose
agar c
37°C 24 h
C. glabrata, C. parapsilosis,
C. guilliermondii, C. krusei,
C. neoformans 30°C 48 h
a,b,c Oxoid, Basingstoke, UK; a supplemented with 5% sheep blood; b
supplemented with 5% horse blood; * cultured in a candle jar.
Wang et al. BMC Infectious Diseases 2013, 13:36 Page 4 of 7
http://www.biomedcentral.com/1471-2334/13/36
[32], α-D-mannosidase activity was invisible by naked
eyes with 6-chloro-3-indolyl-α-D-mannoside as sub-
strate. This may be because the extracellular α-D-mannosi-
dase from these organisms is much less or the enzyme
activity is relatively low. Previous records [31,33-35] on
substrates of α-D-mannosidase mainly involved p-nitrophe-
nol-α-D-mannoside and 4-methylumbelliferyl-α-D-manno-
side. However, 6-chloro-3-indolyl-α-D-mannoside is a
novel chromogenic substrate, and colour reaction of its
chromogen is much more sensitive especially in the case of
the presence of an azo reagent such as fast violet B salt.
Our results showed that clinical specimens such as
urethral discharge, cervical secretions, and vaginal secre-
tions did not interfere with the chromogenic detection
of α-D-mannosidase activity to screen for C. trachoma-
tis, although prostate massage liquid produced more
false positive results. Some human sperm surface pro-
teins possess α-D-mannosidase activity [36], which may
be the reason that prostate specimens produce less reli-
able results. Serotype D was only one of the most preva-
lent (11.1%), and no serovar L2 was found in China [37].
Although the results of this study suggested that other
serotypes, such as serotypes E, F, G, K, H, J, I, and Ba, at
least most of them, might have α-D-mannosidase
activity, there seems to be some limitation of tests on
C. trachomatis cultures based on only one strain of sero-
type D. Further studies and more comprehensive clinical
evaluations should be conducted due to little research
on α-D-mannosidase activity of C. trachomatis. In
addition, our studies did not evaluate C. pneumoniae or
C. psittaci; the α-D-mannosidase activities of these spe-
cies should be studied as well.
Table 4 C. trachomatis detection results of 553 cases with culture, LCR and enzymatic method used an expanded gold
standard as the reference standard
Method No. of true positives/positives No. of true negatives/negatives
Enzymatic method 86/132 413/421
Urethral discharge 22/24 Urethral discharge 126/127
Prostate massage liquid 8/47 Prostate massage liquid 4/5
Cervical secretion 31/33 Cervical secretion 196/199
Vaginal secretion 25/28 Vaginal secretion 87/90
Cell culture 60/60 459/493
Urethral discharge 18/18 Urethral discharge 128/133
Prostate massage liquid 7/7 Prostate massage liquid 43/45
Cervical secretion 21/21 Cervical secretion 198/211
Vaginal secretion 14/14 Vaginal secretion 90/104
LCR 85/89 459/464
Urethral discharge 22/22 Urethral discharge 128/133
Prostate massage liquid 8/8 Prostate massage liquid 43/45
Cervical secretion 32/32 Cervical secretion 198/211
Vaginal secretion 27/27 Vaginal secretion 90/104
Expanded gold standard 94 459
Urethral discharge 23 Urethral discharge 128
Prostate massage liquid 9 Prostate massage liquid 43
Cervical secretion 34 Cervical secretion 198
Vaginal secretion 28 Vaginal secretion 90
Table 5 Clinical performances of three assays for C.
trachomatis using specimens included prostate massage
liquid
Methods % Sensitivity (95% CI) % Specificity (95% CI)
Enzymatic methoda 91.5 (85.9, 97.1) 90.0 (87.3, 92.7)
Cell cultureb 63.8 (54.1, 73.5) 100.0 (100.0, 100.0)
LCRc 94.7 (90.2, 99.2) 100.0 (100.0, 100.0)
a Χ2 = 8.030, P = 0.005, P < 0.05; b Χ2 = 8.721, P = 0.003, P < 0.05; c Χ2 = 0.164,
P = 0.685, P > 0.05.
Table 6 Clinical performances of three assays for C.
trachomatis using specimens excluded prostate massage
liquid
Methods % Sensitivity (95% CI) % Specificity (95% CI)
Enzymatic methoda 91.8 (86.0, 97.6) 98.3 (97.1, 99.5)
Cell cultureb 64.6 (54.3, 74.9) 100.0 (100.0, 100.0)
LCRc 95.3 (90.8, 99.8) 100.0 (100.0, 100.0)
a Χ2 = 0, P = 1, P > 0.05; b Χ2 = 8.605, P = 0.003, P < 0.05; c Χ2 = 0.116,
P = 0.734, P > 0.05.
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Conclusions
The present study demonstrated that there were no sig-
nificant differences between the enzymatic method and
the reference method when prostate specimens were
excluded. Therefore, α-D-mannosidase activity may be a
useful marker for C. trachomatis in urogenital tract spe-
cimens, with many advantages, such as its speed, ease of
use, convenience, and need for no special equipment.
Taken together, these data show that the enzymatic
method has great potential as a clinical method for
C. trachomatis screening.
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